Pharma

Your Article Summary

See Latest Articles

Cytokinetics Announces the Initiation of a First-Time-In-Humans, Phase I Clinical Trial of CK-2017357
Cytokinetics, 06/19/09

Cytokinetics, Incorporated announced that the company has initiated a first-time-in-humans, Phase I clinical trial of CK-2017357 in healthy male volunteers. CK-2017357 is a fast skeletal muscle troponin activator and is the lead drug candidate that has emerged from the company’s skeletal sarcomere activator program. CK-2017357 selectively activates the troponin complex and increases its sensitivity to calcium, subsequently leading to an increase in skeletal muscle force.

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

Cytokinetics announces opening of a phase iia “evidence of effect” clinical trial of ck-2017357 for patients with amyotrophic lateral sclerosis
Cytokinetics, 03/22/10

FDA Advisory Panel Unanimously Recommends Expanded Indication for Boston Scientifics Heart Failure Devices Based on Landmark MADIT-CRT Trial
Boston Scientific, 03/19/10

First Publication of Data from Pivotal Clinical Trial for Medtronic Deep Brain Stimulation Therapy for Epilepsy Published Today in Epilepsia
Medtronic, 03/19/10

 See all of Drug Trials